ESC need-to-know: Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
admin 27th August 2018 Uncategorised 0This year’s big questions for the European Society of Cardiology Congress? Whether Pfizer’s tafamidis can sweep aside Alnylam’s only-just-approved rare disease drug Onpattro, Esperion’s cholesterol hopeful bempedoic acid can find a sweet spot and J&J and Bayer’s Xarelto can turn trial failures into FDA success.
More: ESC need-to-know: Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
Source: fierce